Company intelligence / Profile preview

Andromeda Biotech

Yavne, Israel

Ownership: Private
Development stage: Other

Overview

Andromeda Biotech developed the peptide immunotherapy DiaPep277 targeting newly diagnosed type 1 diabetes, progressing to Phase 3 but discontinued after failure to demonstrate efficacy and findings of major misconduct in data analyses.

Therapeutic areas: Endocrinology
Modalities: Peptides
Industry: Biotech

Partnerships

Clal Biotechnology IndustriesTeva Pharmaceutical Industries

Beyond the preview

Go deeper on Andromeda Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Andromeda Biotech.

Explore the full profile